	US 11,970,541 B2
	Anti-CD20 antibody
Feng Li, Beijing (CN); Boyan Zhang, Foster City, CA (US); and Pei Ye, Lawrenceville, GA (US)
Assigned to BEIJING MABWORKS BIOTECH CO. LTD., Beijing (CN)
Filed by BEIJING MABWORKS BIOTECH CO. LTD., Beijing (CN)
Filed on Nov. 19, 2021, as Appl. No. 17/531,011.
Application 17/531,011 is a division of application No. 16/275,142, filed on Feb. 13, 2019, granted, now 11,208,492.
Application 16/275,142 is a continuation of application No. PCT/CN2017/099287, filed on Aug. 28, 2017.
Prior Publication US 2022/0064321 A1, Mar. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2887 (2013.01) [A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/00 (2018.01); A61P 37/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/41 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/90 (2013.01); C07K 2317/94 (2013.01)]

3 Claims

1. A method for treating an autoimmune disease, comprising administering an effective amount of humanized anti-CD20 antibodies to a subject in need thereof, wherein said humanized anti-CD20 antibodies comprising:

a light chain comprising the amino acid sequence of SEQ ID NO: 1,

a heavy chain comprising the amino acid sequence of SEQ ID NO: 2, and

N-glycans that are attached to the Fc region of the antibody, wherein the N-glycans are not bisected by N-acetylglucosamine, and the N-Glycans comprise G0-GN, G0, G0F, Man5, G1, G1′ and G2.